What's Happening?
Biotalys, a company listed on Euronext, has provided an update on the regulatory approval process for its protein-based biocontrol product, EVOCA, in the United States. The U.S. Environmental Protection Agency (EPA) has confirmed that the scientific review of EVOCA's dossier is progressing, with all requests for additional information addressed. The company anticipates the final steps of the registration procedure to occur in the fourth quarter of 2025, rather than by the end of September as initially expected. EVOCA, developed using Biotalys' AGROBODY technology platform, aims to control fungal diseases like Botrytis and powdery mildew, offering biodegradable solutions to reduce chemical applications for fruit and vegetable growers.
Why It's Important?
The regulatory review of EVOCA is significant as it represents a shift towards precision biocontrols in agriculture, potentially disrupting the industry by providing safer and more sustainable crop protection solutions. This development could benefit growers by reducing reliance on traditional chemical pesticides, aligning with increasing consumer demand for environmentally friendly agricultural practices. Successful registration of EVOCA could enhance Biotalys' market position and create long-term value for investors, while also contributing to the broader adoption of biocontrol technologies in the U.S. agricultural sector.
What's Next?
Biotalys expects to conclude the regulatory review by the end of 2025, with a favorable outcome anticipated for EVOCA. The company continues to engage positively with the EPA, aiming to secure registration for EVOCA, which is not yet available for sale in the U.S. or the European Union. The successful registration could lead to increased adoption of biocontrol products, influencing future regulatory processes and encouraging innovation in sustainable agriculture.
